DYSF encoding dysferlin is mutated in Miyoshi myopathy and Limb-Girdle Muscular Dystrophy type 2B, the two main phenotypes recognized in dysferlinopathies. Dysferlin deficiency in muscle is the most relevant feature for the diagnosis of dysferlinopathy and prompts the search for mutations in DYSF. DYSF, located on chromosome 2p13, contains 55 coding exons and spans 150 kb of genomic DNA. We performed a genomic analysis of the DYSF coding sequence in 34 unrelated patients from various ethnic origins. All patients showed an absence or drastic decrease of dysferlin expression in muscle. A primary screening of DYSF using SSCP or dHPLC of PCR products of each of 55 exons of the gene was followed by sequencing whenever a sequence variation was detected. All together, 54 sequence variations were identified in DYSF, 50 of which predicting either a truncated protein or one amino-acid substitution and most of them (34 out of 54) being novel. In 23 patients, we identified two pathogenic mutations, while only one was identified in 11 patients. These mutations were widely spread in the coding sequence of the gene without any mutational "hotspot."

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.9355DOI Listing

Publication Analysis

Top Keywords

miyoshi myopathy
8
coding sequence
8
dysf
6
dysferlin
4
dysferlin mutations
4
mutations lgmd2b
4
lgmd2b miyoshi
4
myopathy atypical
4
atypical dysferlinopathies
4
dysferlinopathies dysf
4

Similar Publications

Article Synopsis
  • Miyoshi myopathy (MM) is a rare genetic disorder due to mutations in the dysferlin gene, linked to muscle degeneration and recognized as the same disease as Lower Girdle Muscular Dystrophy R2 (LGMD2B).
  • A 44-year-old male patient started experiencing symptoms at 19, including difficulties with stairs and toe-standing, leading to observable muscle atrophy and walking issues over the years.
  • The diagnosis was confirmed through genetic testing, revealing a mutation in the DYSF gene, and highlights the critical role of genetic diagnostics and the need for further research in muscular dystrophies.*
View Article and Find Full Text PDF

Performance of upper limb entry item to predict forced vital capacity in dysferlin-deficient limb girdle muscular dystrophy.

Neuromuscul Disord

October 2024

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon, Tyne, United Kingdom. Electronic address:

Dysferlin-deficient limb girdle muscular dystrophy (LGMD R2), also referred to as dysferlinopathy, can be associated with respiratory muscle weakness as the disease progresses. Clinical practice guidelines recommend biennial lung function assessments in patients with dysferlinopathy to screen for respiratory impairment. However, lack of universal access to spirometry equipment and trained specialists makes regular monitoring challenging.

View Article and Find Full Text PDF
Article Synopsis
  • Miyoshi myopathy/dysferlinopathy (MMD) is a rare muscle disease linked to mutations in the DYSF gene, which also affects the brain's structure and function, although this impact hasn't been fully studied.
  • Using MRI techniques, a family study revealed significant differences in the brain of MMD patients, including an asymmetrical increase in the size of their inferior lateral ventricles and notable decreases in magnesium levels and energy metabolism in brain regions like the hippocampus.
  • Following a month of magnesium supplementation, the MMD patients showed improvements, suggesting potential benefits and calling for more research into the brain functions of MMD patients and further testing of magnesium therapy.
View Article and Find Full Text PDF

Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.

Int J Mol Sci

May 2024

Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA 6150, Australia.

Dysferlin is a large transmembrane protein involved in critical cellular processes including membrane repair and vesicle fusion. Mutations in the dysferlin gene () can result in rare forms of muscular dystrophy; Miyoshi myopathy; limb girdle muscular dystrophy type 2B (LGMD2B); and distal myopathy. These conditions are collectively known as dysferlinopathies and are caused by more than 600 mutations that have been identified across the gene to date.

View Article and Find Full Text PDF

The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.

Biomolecules

February 2024

Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.

Dysferlinopathies refer to a spectrum of muscular dystrophies that cause progressive muscle weakness and degeneration. They are caused by mutations in the gene, which encodes the dysferlin protein that is crucial for repairing muscle membranes. This review delves into the clinical spectra of dysferlinopathies, their molecular mechanisms, and the spectrum of emerging therapeutic strategies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!